Acknowledgements and funding The authors work on gut-derived hormones and obesity-diabetes has been generously supported over many years by Diabetes UK, Invest Northern Ireland, the Irish Endocrine Society, Northern Ireland Department for the Economy, and Ulster University Strategic Funding
More serious side effects are less common but include pancreatitis, gastroparesis, problems with your gallbladder, and bowel obstructions
Of the patients with an HbA1c result at three months, 40% had an HbA1c lower than when they discontinued treatment, and another 48% kept at least some of their improvement
However, no clinical evidence exists demonstrating better outcomes using potent, short-acting DPP-IV inhibitors instead of longer-acting DPP-IV inhibitors, nor has there been a large study on the efficacy of the cleavage products of GLP-1 (7-36) (and GLP-1 [9-37])
International shipping to 30+ countries
Standard practice includes: Baseline thyroid function tests (TSH and free T4) before initiating GLP-1 therapy Repeat testing at 812 weeks after starting treatment or after dose escalation Regular monitoring every 36 months during active weight loss Return to annual monitoring once weight is stable and thyroid function remains consistent Adjustments to levothyroxine dosing may be necessary as weight changes
